PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid (PYPD) reported Q2 2026 milestones: FDA accepted its NDA for D-PLEX100 with Priority Review, setting a PDUFA goal date of November 28, 2026. The company also signed a $320M+ commercialization deal with Azurity Pharmaceuticals for the U.S. and Canada, including upfront payments, milestones, and royalties. PolyPid plans to submit an MAA to the EMA in Q3 2026 and expects a U.S. launch in early 2027.

Original reporting
Published Aug 19, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 4:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PolyPid (PYPD) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

High
01

Why it matters

The regulatory acceptance accelerates the path to market, potentially boosting the stock on the prospect of a 2027 launch, while the partnership adds significant near‑term cash and royalty upside.

02

Market read

New FDA milestone and partnership provide fresh catalyst for PolyPid, creating short‑term trading opportunity.

03

What to watch

manufacturing transfer‑price exposure and reliance on Azurity's commercial execution could affect upside

Relevance 8/10Novelty 8/10Timing: post‑Q2 2026 earnings call

Background

PolyPid announced FDA acceptance of its NDA for D‑PLEX100 with priority review and an exclusive U.S./Canada commercialization deal with Azurity, securing $30 M upfront and up to $290 M in milestones.

Market effects

strengthens biotech/clinical‑stage pharma sector with a new FDA‑priority review candidate

positive for US‑based specialty pharma investors

limited to biotech investors, no broad market effect

Counterpoint

milestone payments are contingent on future regulatory and sales events; risk of delay or failure remains high

Key entities

  • PolyPid

    Biotech firm developing D‑PLEX100

  • Azurity Pharmaceuticals

    Commercial partner for U.S. and Canada

  • FDA

    Granted NDA acceptance and priority review

Related articles

$PYPDMed

PolyPid Ltd. (PYPD): Financial results for Q3 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated

$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

$PYPDHighAI 8/10

Oppenheimer initiates PolyPid stock coverage with outperform rating

Oppenheimer initiated coverage on PolyPid (NASDAQ:PYPD) with an outperform rating and a $10.00 price target. The stock is up 47% over the past year, with a Strong Buy consensus and targets ranging from $8 to $14. PolyPid's D-PLEX100 reduced surgical site infections by 60% in a Phase 3 study and is under FDA Priority Review. The company reported a narrower Q2 2026 loss of $0.35 per share, beating expectations.

$PYPDMed

What PolyPid’s Bold Moves in Europe Could Mean for D-PLEX₁₀₀’s Global Potential (NASDAQ: PYPD) By FinanceWire

PolyPid (NASDAQ: PYPD) announced European Medicines Agency validation of its D-PLEX₁₀₀ Marketing Authorization Application and regained full European commercialization rights. The company's stock rose 15% premarket. D-PLEX₁₀₀, a surgical site infection treatment, has positive Phase 3 data and FDA Priority Review in the U.S. PolyPid aims to partner in Europe on stronger terms than its previous agreement.